NASD · Healthcare · Biotechnology · USA
Harmony Biosciences Holdings Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Harmony Biosciences is a neuroscience company developing treatments for rare neurological diseases, including sleep/wake disorders and rare epilepsy. Its commercial product WAKIX (pitolisant) is an FDA-approved therapy for narcolepsy that works through a novel mechanism targeting histamine signaling in the brain. The company also pursues label expansions and next-generation formulations of pitolisant for other rare neurological conditions.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Harmony Biosciences Holdings Inc stock.
Undervalued: intrinsic value $104.53 per share, market price $37.54, margin of safety 64.1% (as of 2026-10-19).
Discounting its cash flows at 9.7% (average of 3 methods) values the shares at $104.53; the price of $37.54 is 64% below that value, and 75% of that value comes from beyond year five.
Leak Score: 83/100 on 11 of 12 signals (Strong Leak).
17 more funds hold it; the full list is part of the paid plan.
HRMY is undervalued (as of the 2026-10-19 close). Discounting its cash flows at 9.7% (average of 3 methods) values the shares at $104.53; the price of $37.54 is 64% below that value, and 75% of that value comes from beyond year five.
$104.53 per share (as of the 2026-10-19 close), against a market price of $37.54. That is a margin of safety of 64.1%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
83 out of 100, which we rate "Strong Leak", on 11 of 12 value investing signals.